This document is an excerpt from the EUR-Lex website
Public-private partnership in innovative medicines
WHAT IS THE AIM OF THE REGULATION?
It establishes the second phase of the Innovative Medicines Initiative (IMI) Joint Undertaking (JU) for the period from 2014 to 2020.
The IMI 2 JU aims to develop new vaccines, medicines and treatments. This is done by means of joint research projects to address Europe’s health challenges and to ensure that Europe’s pharmaceutical industry remains competitive.
Strategic Research Agenda
IMI 2’s focus is on 4 areas of research:
target validation and biomarker* research (efficacy and safety);
adoption of innovative clinical trial paradigms;
patient-tailored adherence (the extent to which patients take the treatment that they are prescribed, as directed) programmes.
Health priorities to be addressed by IMI include:
The EU’s contribution to IMI 2 is up to €1,638 billion for the period to 2024. This will be matched by €1,425 billion committed by the pharmaceutical industry (in-kind contributions). Additional funding comes from other life science industries or organisations that decide to contribute to IMI 2 as members or associated partners in individual projects. The JU also seeks to develop synergies with the European Structural and Investment Funds.
FROM WHEN DOES THE REGULATION APPLY?
It has applied since 27 June 2014.
For more information, see:
Council Regulation (EU) No 557/2014 of 6 May 2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking (OJ L 169, 7.6.2014, pp. 54-76)
Commission Delegated Regulation (EU) No 622/2014 of 14 February 2014 establishing a derogation from Regulation (EU) No 1290/2013 of the European Parliament and of the Council laying down the rules for participation and dissemination in ‘Horizon 2020 — the Framework Programme for Research and Innovation (2014-2020)’ with regard to the Innovative Medicines Initiative 2 Joint Undertaking (OJ L 174, 13.6.2014, pp. 7-11)
Regulation (EU) No 1290/2013 of the European Parliament and of the Council of 11 December 2013 laying down the rules for participation and dissemination in ‘Horizon 2020 — the Framework Programme for Research and Innovation (2014-2020)’ and repealing Regulation (EC) No 1906/2006 (OJ L 347, 20.12.2013, pp. 81-103)
Regulation (EU) No 1291/2013 of the European Parliament and of the Council of 11 December 2013 establishing ‘Horizon 2020 — the Framework Programme for Research and Innovation (2014-2020)’ and repealing Decision No 1982/2006/EC (OJ L 347, 20.12.2013, pp. 104-173)
Successive amendments to Regulation (EU) No 1291/2013 have been incorporated into the original document. This consolidated version is of documentary value only.
last update 21.08.2018